3'-DEOXY-3'-[(PHENYLMETHYL)AMINO]-ADENOSINE, 95.0%, 250mg

D-luciferina, mínimo 99 %, para bioquímica, 25 mg, envase de vidrio

(3aR,4R,5R,6aS)-2-Oxo-4-((R,E)-3-oxo-4-(m-tolyl)pent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl benzoate, 98%, 50mg

(S)-1-(4-(Methylthio)phenyl)ethan-1-amine hydrochloride, 97%, 1g

(R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-methyloct-7-enoic acid, 95.0%, 1g

2-Bromo-1-fluoro-4-iodobenzene, 98.0%, 100g

Methylpiperazine-1-carboxylate, 98.00%, 1kg

3,5-dibromo-1-[2-(1,3-dioxan-2-yl)ethyl]-1H-1,2,4-triazole, 95.0%, 1g

Methyl 1H-indene-3-carboxylate, 95.0%, 25g

4-methylquinoline-6-carboxylic acid, 95.0%, 1g

1-methyl-N-[3-(trifluoromethyl)phenyl]-1-hydrazinecarbothioamide, 95%, 1g

tert-Butyl 7-acetyl-2,7-diazaspiro[3.5]nonane-2-carboxylate, 95.0%, 250mg

tert-Butyl 2-hydroxy-1H-benzo[d]imidazole-1-carboxylate, 95.0%, 250mg